How did Dr. Hallberg discover the efficacy of carbohydrate restriction for Type 2 Diabetes?

After growing frustrated with traditional low-calorie, low-fat advice that yielded poor patient outcomes, Dr. Hallberg was given time to research and discovered carbohydrate restriction. Influenced by Drs. Stephen Phinney and Jeff Volek, she implemented it in her obesity clinic, observing miraculous reversals of Type 2 Diabetes.

What resistance did Dr. Hallberg face introducing an unconventional diet approach?

Dr. Hallberg took precautions by presenting her evidence to various departments at Indiana University Health, preempting pushback. Surprisingly, she received unanimous support from the ambulatory quality committee to offer carbohydrate restriction as an option for metabolic disease patients, changing her life and career.

What are the latest statistics on metabolic health in America?

Recent studies indicate that over 50% of adult Americans have diabetes or pre-diabetes. Alarmingly, NHANES data suggests that 88% of adult Americans are not in optimal metabolic health, defined by criteria for metabolic syndrome.

What is the significance of early detection of pre-diabetes?

By the time a patient is diagnosed with pre-diabetes, significant damage, including impacts on vision and nerves, has already occurred over 5-10 years. Ignoring any blood sugar elevation means a problem has existed for a long time, emphasizing the need for early intervention.

How does exogenous (dietary) saturated fat intake relate to endogenous (serum) saturated fat levels?

Clinical trials, such as the one by Dr. Brittany Volk, demonstrate that high dietary saturated fat intake in a low-carbohydrate environment does not lead to higher serum saturated fatty acid levels. In fact, serum saturated fat can be higher with lower dietary saturated fat but higher carbohydrate intake, challenging the 'you are what you eat' dogma.

Why is palmitoleic acid (POA) considered an important health biomarker?

Palmitoleic acid (POA), a product of steroyl-CoA desaturase 1 (SCD-1), is an independent marker of triglyceridemia and abdominal adiposity, highly correlated with insulin resistance. Elevated POA levels predict future diabetes and health problems even in individuals with normal blood sugar, serving as an early warning sign of carbohydrate intolerance.

How does the body protect itself from excessive carbohydrate consumption?

The liver, in response to carbohydrate consumption above an individual's tolerance, converts excess carbohydrate into fat through de novo lipogenesis. This fat, including palmitoleic acid (POA), is then exported from the liver via VLDL particles to adipose tissue. This process is seen as the body's protective mechanism to manage nutritional abundance and minimize liver damage.

Can insulin sensitivity be reset through carbohydrate restriction?

Yes, Dr. Hallberg observes that many patients with long-standing diabetes can reverse their disease and normalize blood glucose through very low carbohydrate diets. Some can even reintroduce carbohydrates later, suggesting a 'reset' of the system and a return of beta-cell function, though the extent varies by individual insulin reserve.

What are the risks of continuous insulin use for Type 2 Diabetes?

While insulin is crucial for acute glycemic control, its long-term use, especially in high doses, can lead to weight gain and is associated with increased mortality risk. Dr. Hallberg advocates for a 'mandatory discussion' with patients about these risks, urging providers to focus on disease reversal rather than just management.

What type of lung cancer was Dr. Hallberg diagnosed with, and how is it characterized?

Dr. Hallberg was diagnosed with stage four EGFR exon 19 mutation-driven non-small cell adenocarcinoma, a type of lung cancer increasingly found in non-smokers, particularly young, thin, and athletic women. This type of cancer has specific targeted therapies but often returns.

How did Dr. Hallberg cope with her terminal cancer diagnosis emotionally?

Initially, Dr. Hallberg experienced overwhelming grief and denial, leading her to consider physician-assisted suicide. However, driven by her children's need for her and her desire to continue her work, she eventually embraced acceptance and made a conscious choice to live fully, despite the terminal nature of her illness.

What was Dr. Hallberg's '11-year goal' after her diagnosis?

After her diagnosis, Dr. Hallberg set a personal goal to live for at least 11 more years, which would allow her youngest child to graduate. This became her 'war cry' and a powerful motivator to pursue aggressive and innovative treatments.

What challenges did Dr. Hallberg face during her ongoing cancer treatment?

Dr. Hallberg experienced initial relief with TKIs, followed by a surgical setback where her primary lung tumor couldn't be removed due to mediastinal involvement. She then pursued an aggressive, constantly changing chemotherapy regimen because she refused to be a 'sitting duck' and wait for recurrence. She also suffered multi-organ failure from a rare reaction to Gemcitabine chemotherapy.

How has Dr. Hallberg's cancer experience influenced her advocacy for health equity?

Her personal experience highlighted the stark disparities in cancer survival based on privilege and access to resources. The four-month delay she faced in getting treatment for her recurrence, despite her expert self-advocacy, made her deeply committed to working for health equity in both diabetes and cancer care, realizing that many others die during such delays.

Key Moments

#162 - Sarah Hallberg, D.O., M.S.: Treating metabolic disease, & a personal journey through cancer

Q: Why is the role of dietary fat and carbohydrate intake on fatty acid distribution important?

Understanding this relationship is crucial because it counters the common belief of 'you are what you eat,' especially regarding saturated fat. In the context of carbohydrate restriction, dietary saturated fat intake does not directly correlate with serum saturated fat levels, and it helps decrease cardiovascular and diabetes risk biomarkers by reversing related metabolic dysregulations.

Peter Attia MD

People & Blogs3 min read150 min video

May 17, 2021|197,547 views|4,887|591

sarah hallberg type 2 diabetes metabolic disease low carb diet

Save to Pod

Key Moments

TL;DR

Dr. Sarah Hallberg discusses metabolic disease, cancer, and advocating for health equity.

Key Insights

Carbohydrate restriction offers a powerful therapeutic approach for type 2 diabetes and metabolic syndrome.

Palmitoleic acid (16:1) may serve as an early biomarker for metabolic dysfunction, preceding blood sugar changes.

Obesity can be a result, not a cause, of metabolic disease, highlighting the need for compassionate care.

Sarah Hallberg's personal journey with stage IV lung cancer underscores the importance of aggressive treatment and patient advocacy.

Health disparities are significant in both metabolic disease and cancer treatment, necessitating a focus on health equity.

The medical system often fails patients when cancer recurs, demanding greater advocacy and more efficient re-treatment pathways.

THE PHYSIOLOGICAL ROLE OF DIETARY FAT

Dr. Sarah Hallberg emphasizes the critical role of dietary intake, particularly carbohydrates and fats, in influencing fatty acid distribution and metabolic health. She challenges the simplistic 'you are what you eat' adage, especially concerning saturated fats. Hallberg highlights how carbohydrate restriction can improve cardiovascular risk biomarkers and even reverse type 2 diabetes, underscoring the complexity of fatty acid metabolism that often goes undiscussed due to its confusing nature.

APhysician's JOURNEY: FROM OBESITY CARE TO METABOLIC BREAKTHROUGH

Hallberg shares her personal and professional evolution, moving from traditional low-fat, low-calorie dietary advice to embracing carbohydrate restriction. Frustrated by the lack of progress in primary care, she pivoted to leading an obesity program. There, she discovered the profound impact of carbohydrate restriction on reversing type 2 diabetes, a discovery that challenged decades of her prior medical training and ignited a passion for research and evidence-based metabolic interventions.

THE PREVALENCE OF METABOLIC DYSFUNCTION

The conversation delves into the alarming prevalence of metabolic diseases in the U.S., with over 50% of adults having diabetes or pre-diabetes. Furthermore, 88% of American adults are not in optimal metabolic health, as indicated by criteria for metabolic syndrome. Hallberg stresses that 'normal' blood sugar does not equate to health and that pre-diabetes signifies significant underlying issues that have been progressing for years, impacting microvascular health even before formal diagnosis.

PALMITOLEIC ACID AS AN EARLY BIOMARKER

Hallberg introduces palmitoleic acid (16:1) as a potentially crucial biomarker for early metabolic dysfunction. Its production, facilitated by the enzyme SCD-1, increases with carbohydrate consumption above an individual's tolerance threshold. Elevated palmitoleic acid levels, often correlating with higher triglycerides, may indicate impending insulin resistance and metabolic issues even when fasting glucose remains normal, suggesting it could serve as an early warning sign for intervention.

NAVIGATING A STAGE IV LUNG CANCER DIAGNOSIS

Hallberg recounts her unexpected diagnosis of stage IV lung cancer, despite being a healthy non-smoker. The experience marked a profound personal shift, forcing her to confront mortality, grief, and the aggressive realities of cancer treatment. She initially grappled with the diagnosis, contemplating physician-assisted suicide, but ultimately chose to fight, driven by her role as a mother and her desire to live for her children.

THE FIGHT FOR EQUAL ACCESS AND HEALTH EQUITY

Hallberg's cancer journey has amplified her commitment to health equity. She highlights the significant disparities in healthcare access and outcomes, particularly for cancer patients and those with chronic diseases. Her personal experience with advanced cancer treatment, including delays in care and high out-of-pocket costs, underscores the systemic challenges faced by many, motivating her to advocate for improved access and more equitable treatment pathways for all.

ADVOCACY, RESILIENCE, AND CONTINUED FIGHT

Despite enduring multiple treatments, including chemotherapy, radiation, and targeted therapies, Hallberg maintains a resolute spirit. She emphasizes the importance of proactive advocacy, seeking aggressive treatment, and managing her condition rather than passively waiting for progression. Her journey has reshaped her perspective, not by discovering a new purpose, but by deepening her commitment to her existing values and advocating for both metabolic health and cancer patient rights.

Mentioned in This Episode

●Software & Apps

●Companies

●Organizations

●Books

●Studies Cited

●Concepts

●People Referenced

Impact of Diet on Fatty Acid Levels (Volk Study)

Data extracted from this episode

Dietary Saturated Fat Intake (g/day)	Carbohydrate Intake (g/day)	Serum Saturated Fatty Acids (16:0) - Change Trend	Palmitoleic Acid (16:1) - Change Trend
84 (High)	<50 (Very Low)	Stable/Slight Decrease	Significant Decrease
32 (Low)	346 (High)	Trend to Higher	Significant Increase

Dietary Intervention Effects on Triglycerides and Fatty Acids (Volek Study)

Data extracted from this episode

Diet Group	Calories/Day (approx.)	Dietary Saturated Fat (g)	Baseline Triglycerides (mg/dL)	Change in Triglycerides (%)	Change in Total Saturated Fatty Acids (relative %)	Change in Palmitoleic Acid (16:1) (relative %)
Very Low Carbohydrate	1500	36	211	-50%	-12%	Significant Decrease
Low Fat	1500	12	187	-20%	-5%	Significant Increase

Common Questions

Understanding this relationship is crucial because it counters the common belief of 'you are what you eat,' especially regarding saturated fat. In the context of carbohydrate restriction, dietary saturated fat intake does not directly correlate with serum saturated fat levels, and it helps decrease cardiovascular and diabetes risk biomarkers by reversing related metabolic dysregulations.

Topics

Mental Health & Psychology Insulin Resistance Metabolic Syndrome Health Equity Type 2 Diabetes Reversal Patient Advocacy Medicine & Clinical Carbohydrate Restriction Fatty Acid Metabolism Cancer Diagnosis Lung Cancer Treatment Coping With Illness

Mentioned in this video

Organizations

Purdue University

Dr. Hallberg initiated an unfunded pilot study with researchers from Purdue University's nutrition program to examine metabolic and financial improvements.

National Lipid Association

An association where Dr. Hallberg presented findings from her pilot study, a precursor to her TED Talk.

Obesity Medicine Association

A conference where Dr. Hallberg met Dr. Stephen Phinney, leading to the funding of larger clinical trials.

Aspen Institute

An organization that selected Dr. Hallberg as an Aspen Health Innovator Fellow, an honor that influenced her decision to continue her work despite her cancer diagnosis.

The Guardian

Mentioned as having published a story about non-smoking lung cancer, highlighting its growing prevalence and impact.

Indiana University Health

The institution where Dr. Hallberg was asked to start an obesity program, leading to her discovery of carbohydrate restriction.

American Diabetes Association

Dr. Hallberg discusses the traditional approaches to diabetes management promoted at ADA meetings versus her own experiences with carbohydrate restriction.

People

Brittany Volk

A researcher cited for her feeding study on metabolic syndrome patients, which monitored fatty acid changes across different carbohydrate intake phases.

Jeff Volek

Along with Stephen Phinney, he co-authored an important book on metabolic health that deeply resonated with Dr. Hallberg and Peter Attia.

Eric Westman

Mentioned as one of the pioneers in carbohydrate restriction research, alongside Drs. Phinney and Volek.

Stephen Phinney

A researcher whose lectures on carbohydrate restriction significantly influenced Dr. Hallberg's approach to obesity and diabetes.

Jerry Shulman

Referenced as a guest on a previous podcast episode who elegantly explained the long time course of insulin resistance.

Companies

Verta Health

A company focused on remotely treating patients with Type 2 Diabetes, co-founded by Dr. Hallberg, Dr. Stephen Phinney, and Dr. Jeff Volek.

Concepts

Epidermal Growth Factor Receptor (EGFR) mutation

A specific genetic mutation found in Dr. Hallberg's non-small cell lung cancer, for which targeted therapies exist.

Atypical Hemolytic Uremic Syndrome

A rare and severe complication Dr. Hallberg developed from Gemcitabine chemotherapy, leading to multi-organ failure.

Palmitoleic Acid

A monounsaturated fatty acid that the discussion highlights as a more important health predictor than often appreciated, correlating with insulin resistance markers.

Pharmacogenetics

The study of how genes affect a person's response to drugs, which identified Dr. Hallberg's genetic mutation explaining her adverse reaction to Gemzar.

C-reactive protein

Discussed as a marker in a Netherlands study correlating palmitoleic acid levels at age 50 with CRP levels at age 70, indicating its predictive power for future health problems.

Steroyl-CoA Desaturase 1

An enzyme that converts saturated fatty acids like palmitic acid into palmitoleic acid, with increased activity being an independent marker for triglyceridemia and abdominal adiposity.

Type 2 Diabetes

A chronic progressive disease that Dr. Hallberg became passionate about managing through unconventional, non-standard treatments.

Drugs & Medications

Fulvestrant

Another anti-estrogen therapy medication Dr. Hallberg was prescribed, placing her into early menopause as part of her treatment strategy.

Osimertinib

A newer generation TKI that Dr. Hallberg was switched to after the initial TKI failed, used to treat her EGFR-mutated lung cancer.

Gemcitabine

A chemotherapy drug that caused severe, life-threatening complications for Dr. Hallberg due to a genetic mutation preventing its breakdown.

Palbociclib

Primarily a breast cancer medication used to target one of Dr. Hallberg's specific secondary mutations.

Tyrosine Kinase Inhibitors

A class of targeted therapy medications used to treat EGFR-driven cancers, effective but with a limited duration before resistance develops.

Studies & Research

NHANES data

National Health and Nutrition Examination Survey data, cited for the statistic that 88% of adult Americans are not in optimal metabolic health.

Supplements

Lupron

One of the anti-estrogen therapy medications Dr. Hallberg was prescribed, placing her into early menopause as part of her treatment strategy.

Cisplatin

A chemotherapy drug Dr. Hallberg received, which is known for its harsh side effects.

Books

The Art and Science of Low Carbohydrate Living

A book by Drs. Stephen Phinney and Jeff Volek, which was highly influential for Peter Attia in his understanding of low-carb diets.

Media

TED Talk

Dr. Hallberg referenced her TED Talk where she discussed her pilot study's findings on metabolic and financial improvements in diabetes.

Locations

Oregon

Dr. Hallberg initially wanted to move to Oregon due to its physician-assisted suicide laws, reflecting her initial despair after her cancer diagnosis.

Products

Continuous Glucose Monitor

A device used in Peter Attia's practice for non-diabetics to maintain high standards for average glucose and manage excursions, recognizing early signs of metabolic issues.